GLP-1受体激动剂与不良妊娠结局风险的系统评价与荟萃分析
主要分析未发现妊娠期糖尿病、早产、子痫前期或妊娠期高血压疾病风险显著改变,但留一法敏感性分析提示暴露可能降低妊娠期糖尿病风险。
要点
- 围受精期GLP-1受体激动剂暴露未显著改变母体妊娠并发症的总体风险。
- 留一法敏感性分析提示暴露可能降低妊娠期糖尿病风险(OR 0.81,95%CI 0.67-0.98)。
- 研究间异质性高,源于暴露与结局定义、队列选择及混杂控制差异。
核心结论
- 围受精期使用GLP-1受体激动剂与母体妊娠并发症风险改变无关。
- 探索性敏感性结果提示围受精期暴露可能降低妊娠期糖尿病风险。
研究设计与样本
- 纳入8项研究共186,598例妊娠,其中暴露组47,159例。
- 纳入标准为孕前或孕期暴露于GLP-1受体激动剂、报告母体产科结局定量数据的队列、病例对照或RCT研究,且研究人群大于10。
- 采用随机效应模型合并OR,使用Knapp-Hartung调整和限制性最大似然估计量进行异质性检验。
主要发现
- 妊娠期糖尿病OR 0.99(95%CI 0.61-1.61),无统计学显著差异。
- 早产OR 1.01(95%CI 0.76-1.33),无统计学显著差异。
- 子痫前期OR 1.05(95%CI 0.60-1.84),无统计学显著差异。
- 妊娠期高血压疾病OR 0.79(95%CI 0.34-1.83),无统计学显著差异。
- 留一法敏感性分析提示GLP-1受体激动剂暴露可能对妊娠期糖尿病有保护作用(OR 0.81,95%CI 0.67-0.98)。
关键数值与推荐
- 主要分析中妊娠期糖尿病、早产、子痫前期、妊娠期高血压疾病的合并OR均无统计学显著性。
- 留一法敏感性分析中妊娠期糖尿病OR 0.81(95%CI 0.67-0.98)。
- 纽卡斯尔-渥太华量表评估显示研究质量存在变异性,异质性高。
临床怎么用
- 围受精期GLP-1受体激动剂暴露未显示增加母体妊娠并发症风险,可作为咨询参考。
- 关于妊娠期糖尿病风险降低的敏感性分析结果属假设生成性,需进一步研究验证。
局限性
- 研究间异质性高,源于暴露与结局定义、队列选择及混杂控制差异。
- 纳入研究质量存在变异性。
- 敏感性分析结果仅为探索性,需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess associations between pregestational and early-gestational exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and maternal pregnancy complications. DATA SOURCES: A comprehensive search across the PubMed and EMBASE databases was conducted from inception to November 2025. METHODS OF STUDY SELECTION: Eligibility criteria for inclusion were 1) exposure to GLP-1 RAs before or during gestation; 2) cohort, case-control, or randomized controlled trial (RCT) study reporting quantitative data on maternal obstetric outcomes; and 3) study population greater than 10. Two reviewers independently abstracted study data and assessed quality and risk of bias using the Newcastle-Ottawa Quality Assessment Scale for observational studies and the Risk of Bias for Randomized Crossover Trials tool for RCTs. Odds ratios (ORs) were pooled using random effects with the Knapp-Hartung adjustment to reduce chance of false-positives and the restricted maximum likelihood estimator for heterogeneity testing. TABULATION, INTEGRATION, AND RESULTS: Eight studies totaling 186,598 pregnancies (47,159 exposed) were included. No statistically significant differences were seen for gestational diabetes (OR 0.99, 95% CI, 0.61-1.61), preterm birth (OR 1.01, 95% CI, 0.76-1.33), preeclampsia (OR 1.05, 95% CI, 0.60-1.84), or hypertensive disorder of pregnancy (OR 0.79, 95% CI, 0.34-1.83), although results from leave-one-out sensitivity testing suggest that GLP-1 RA exposure may have a protective effect against developing gestational diabetes (OR 0.81, 95% CI, 0.67-0.98). Newcastle-Ottawa Quality Assessment Scale results demonstrated variability in study quality and high heterogeneity attributable to differences in exposure and outcome definitions, cohort selection, and control for confounders. CONCLUSION: Use of a GLP-1 RA in the peri-fertilization period was not associated with change in odds of maternal pregnancy complications. Exploratory sensitivity results suggest that peri-fertilization exposure may lower odds of gestational diabetes. Further research is necessary to explore these hypotheses-generating results.
引用
- Hattler E, Schluter H, Greene C, et al. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Adverse Maternal Pregnancy Outcomes: A Systematic Review and Meta-analysis. Obstet Gynecol. 2026. PMID: 42391628. doi:10.1097/AOG.0000000000006363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。